A detailed history of Manufacturers Life Insurance Company, The transactions in Arvinas, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 95,105 shares of ARVN stock, worth $2.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
95,105
Previous 119,481 20.4%
Holding current value
$2.58 Million
Previous $4.93 Million 48.68%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$24.46 - $40.4 $596,236 - $984,790
-24,376 Reduced 20.4%
95,105 $2.53 Million
Q1 2024

May 14, 2024

BUY
$36.38 - $52.31 $1.1 Million - $1.58 Million
30,253 Added 33.91%
119,481 $4.93 Million
Q4 2023

Feb 13, 2024

BUY
$14.19 - $42.33 $310,917 - $927,492
21,911 Added 32.55%
89,228 $3.67 Million
Q3 2023

Nov 15, 2023

BUY
$19.64 - $28.21 $112,812 - $162,038
5,744 Added 9.33%
67,317 $1.32 Million
Q2 2023

Aug 11, 2023

BUY
$21.73 - $31.43 $133,943 - $193,734
6,164 Added 11.12%
61,573 $1.53 Million
Q1 2023

May 15, 2023

BUY
$26.15 - $37.26 $2,641 - $3,763
101 Added 0.18%
55,510 $1.52 Million
Q4 2022

Aug 11, 2023

BUY
$32.47 - $57.24 $176,571 - $311,271
5,438 Added 10.88%
55,409 $1.9 Million
Q4 2022

Feb 13, 2023

BUY
$32.47 - $57.24 $176,571 - $311,271
5,438 Added 10.88%
55,409 $1.9 Million
Q3 2022

Aug 11, 2023

SELL
$41.87 - $57.99 $18,087 - $25,051
-432 Reduced 0.86%
49,971 $2.22 Million
Q3 2022

Nov 03, 2022

SELL
$41.87 - $57.99 $18,087 - $25,051
-432 Reduced 0.86%
49,971 $2.23 Million
Q2 2022

Aug 11, 2023

BUY
$36.01 - $74.24 $18,077 - $37,268
502 Added 1.01%
50,403 $2.12 Million
Q2 2022

Aug 15, 2022

BUY
$36.01 - $74.24 $18,077 - $37,268
502 Added 1.01%
50,403 $2.17 Million
Q1 2022

Aug 11, 2023

SELL
$60.27 - $81.57 $338,054 - $457,526
-5,609 Reduced 10.1%
49,901 $3.36 Million
Q1 2022

May 20, 2022

BUY
$60.27 - $81.57 $1.6 Million - $2.16 Million
26,522 Added 113.44%
49,901 $3.25 Million
Q4 2021

Feb 16, 2022

BUY
$65.85 - $96.21 $69,274 - $101,212
1,052 Added 4.71%
23,379 $1.89 Million
Q3 2021

Nov 12, 2021

SELL
$73.2 - $107.87 $156,501 - $230,626
-2,138 Reduced 8.74%
22,327 $1.84 Million
Q2 2021

Aug 12, 2021

BUY
$60.45 - $84.26 $244,459 - $340,747
4,044 Added 19.8%
24,465 $1.88 Million
Q1 2021

May 03, 2021

SELL
$58.19 - $91.37 $23,857 - $37,461
-410 Reduced 1.97%
20,421 $1.35 Million
Q4 2020

Feb 12, 2021

BUY
$20.19 - $84.93 $69,817 - $293,687
3,458 Added 19.9%
20,831 $1.77 Million
Q3 2020

Nov 09, 2020

SELL
$22.99 - $36.34 $8,138 - $12,864
-354 Reduced 2.0%
17,373 $410,000
Q2 2020

Aug 10, 2020

BUY
$29.88 - $56.74 $114,380 - $217,200
3,828 Added 27.54%
17,727 $566,000
Q1 2020

May 15, 2020

BUY
$33.0 - $54.5 $74,151 - $122,461
2,247 Added 19.28%
13,899 $560,000
Q4 2019

Feb 14, 2020

SELL
$15.39 - $44.38 $3,355 - $9,674
-218 Reduced 1.84%
11,652 $479,000
Q3 2019

Nov 12, 2019

BUY
$21.55 - $27.61 $8,469 - $10,850
393 Added 3.42%
11,870 $270,000
Q2 2019

Aug 14, 2019

BUY
$15.96 - $23.8 $183,172 - $273,152
11,477 New
11,477 $252,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.44B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.